Chronic myeloid leukemia

Current treatment options

John M. Goldman, Brian Druker

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to this result; conversely, only a minority of patients are eligible for transplantation, which still carries an appreciable risk for death or protracted illness. For most patients, interferon-α (IFN-α) prolongs life to some degree in comparison with hydroxyurea, but it is associated with considerable toxicity. The newly introduced tyrosine kinase inhibitor STI571 induces complete hematologic remission in almost all patients and is associated with a very high rate of cytogenetic response; its capacity to prolong life in comparison with IFN-α is not yet established. Here are reviewed some factors that predict survival after nontransplantation therapy and after allografting for CML in chronic phase. Two contrasting options are considered for managing the patient with newly diagnosed disease, and it can be concluded that, for now, allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients. Further experience with the use of STI571 as a single agent or in combination with other antileukemic agents may alter the picture in the near future.

Original languageEnglish (US)
Pages (from-to)2039-2042
Number of pages4
JournalBlood
Volume98
Issue number7
DOIs
StatePublished - Oct 1 2001

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Interferons
Transplantation (surgical)
Hydroxyurea
Grafts
Protein-Tyrosine Kinases
Toxicity
Stem Cell Transplantation
Leukemia
Therapeutics
Leukemia, Myeloid, Chronic Phase
Homologous Transplantation
Cytogenetics
Imatinib Mesylate
Transplantation
Transplants
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myeloid leukemia : Current treatment options. / Goldman, John M.; Druker, Brian.

In: Blood, Vol. 98, No. 7, 01.10.2001, p. 2039-2042.

Research output: Contribution to journalArticle

Goldman, John M. ; Druker, Brian. / Chronic myeloid leukemia : Current treatment options. In: Blood. 2001 ; Vol. 98, No. 7. pp. 2039-2042.
@article{50d8cfd25ba148919b46bb7c953a1387,
title = "Chronic myeloid leukemia: Current treatment options",
abstract = "The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to this result; conversely, only a minority of patients are eligible for transplantation, which still carries an appreciable risk for death or protracted illness. For most patients, interferon-α (IFN-α) prolongs life to some degree in comparison with hydroxyurea, but it is associated with considerable toxicity. The newly introduced tyrosine kinase inhibitor STI571 induces complete hematologic remission in almost all patients and is associated with a very high rate of cytogenetic response; its capacity to prolong life in comparison with IFN-α is not yet established. Here are reviewed some factors that predict survival after nontransplantation therapy and after allografting for CML in chronic phase. Two contrasting options are considered for managing the patient with newly diagnosed disease, and it can be concluded that, for now, allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients. Further experience with the use of STI571 as a single agent or in combination with other antileukemic agents may alter the picture in the near future.",
author = "Goldman, {John M.} and Brian Druker",
year = "2001",
month = "10",
day = "1",
doi = "10.1182/blood.V98.7.2039",
language = "English (US)",
volume = "98",
pages = "2039--2042",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Chronic myeloid leukemia

T2 - Current treatment options

AU - Goldman, John M.

AU - Druker, Brian

PY - 2001/10/1

Y1 - 2001/10/1

N2 - The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to this result; conversely, only a minority of patients are eligible for transplantation, which still carries an appreciable risk for death or protracted illness. For most patients, interferon-α (IFN-α) prolongs life to some degree in comparison with hydroxyurea, but it is associated with considerable toxicity. The newly introduced tyrosine kinase inhibitor STI571 induces complete hematologic remission in almost all patients and is associated with a very high rate of cytogenetic response; its capacity to prolong life in comparison with IFN-α is not yet established. Here are reviewed some factors that predict survival after nontransplantation therapy and after allografting for CML in chronic phase. Two contrasting options are considered for managing the patient with newly diagnosed disease, and it can be concluded that, for now, allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients. Further experience with the use of STI571 as a single agent or in combination with other antileukemic agents may alter the picture in the near future.

AB - The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to this result; conversely, only a minority of patients are eligible for transplantation, which still carries an appreciable risk for death or protracted illness. For most patients, interferon-α (IFN-α) prolongs life to some degree in comparison with hydroxyurea, but it is associated with considerable toxicity. The newly introduced tyrosine kinase inhibitor STI571 induces complete hematologic remission in almost all patients and is associated with a very high rate of cytogenetic response; its capacity to prolong life in comparison with IFN-α is not yet established. Here are reviewed some factors that predict survival after nontransplantation therapy and after allografting for CML in chronic phase. Two contrasting options are considered for managing the patient with newly diagnosed disease, and it can be concluded that, for now, allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients. Further experience with the use of STI571 as a single agent or in combination with other antileukemic agents may alter the picture in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0035496899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035496899&partnerID=8YFLogxK

U2 - 10.1182/blood.V98.7.2039

DO - 10.1182/blood.V98.7.2039

M3 - Article

VL - 98

SP - 2039

EP - 2042

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -